| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.41B | 11.27B | 8.83B | 7.72B | 6.70B | 5.58B |
| Gross Profit | 1.53B | 1.59B | 1.43B | 1.35B | 1.25B | 1.05B |
| EBITDA | 445.83M | 398.13M | 349.52M | 391.80M | 433.34M | 346.69M |
| Net Income | 129.59M | -18.06M | -154.60M | -53.91M | 49.80M | 20.81M |
Balance Sheet | ||||||
| Total Assets | 6.05B | 5.93B | 5.53B | 5.44B | 5.51B | 4.54B |
| Cash, Cash Equivalents and Short-Term Investments | 140.34M | 61.25M | 13.07M | 13.63M | 46.73M | 262.00M |
| Total Debt | 2.70B | 2.90B | 3.67B | 3.68B | 3.77B | 2.97B |
| Total Liabilities | 4.23B | 4.27B | 4.92B | 4.66B | 4.71B | 3.81B |
| Stockholders Equity | 1.82B | 1.65B | 584.74M | 754.78M | 774.82M | 704.98M |
Cash Flow | ||||||
| Free Cash Flow | 276.09M | -57.14M | 137.26M | -74.77M | 210.90M | 170.73M |
| Operating Cash Flow | 349.22M | 23.77M | 210.78M | -4.65M | 270.17M | 222.64M |
| Investing Cash Flow | -86.97M | -140.24M | -134.43M | 45.36M | -1.19B | -451.85M |
| Financing Cash Flow | -156.92M | 164.65M | -76.91M | -73.81M | 705.22M | 472.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.19B | 39.31 | 11.37% | ― | 11.41% | 8.70% | |
75 Outperform | $3.03B | 211.21 | 2.74% | ― | 19.01% | 38.68% | |
67 Neutral | $5.78B | 53.47 | 4.25% | ― | 17.23% | ― | |
64 Neutral | $3.45B | ― | ― | ― | 50.67% | -578.00% | |
62 Neutral | $2.33B | -102.92 | 0.42% | 2.98% | -21.26% | -119.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $395.07M | ― | -13.63% | ― | -16.65% | -71.92% |
BrightSpring Health Services’ recent earnings call painted a picture of robust financial health, underscored by notable revenue and EBITDA growth. The sentiment was overwhelmingly positive, reflecting strong performance in Pharmacy Solutions and operational efficiencies. Despite facing hurdles in the Home & Community Pharmacy segment and a delay in the divestiture of the Community Living business, the company remains optimistic, bolstered by increased guidance for 2025 and ongoing investments in quality and efficiency.
BrightSpring Health Services, Inc. is a prominent provider of home and community-based health services, focusing on complex populations with specialized and chronic care needs across the United States. The company operates in the healthcare sector, delivering integrated care solutions through various service lines, including pharmacy, home health care, and rehabilitation.
On October 20, 2025, BrightSpring Health Services, Inc. entered into an underwriting agreement with KKR Phoenix Aggregator L.P., Management Selling Stockholders, and BofA Securities, Inc. for an underwritten offering of 15,000,000 shares of its common stock. The offering, which closed on October 22, 2025, involved the sale of shares by the Selling Stockholders, with the company not receiving any proceeds except from the exercise of stock options by management. BrightSpring also repurchased 1,500,000 shares from the underwriter without incurring underwriting fees. This transaction was conducted under an automatic shelf registration statement filed with the SEC, and included customary conditions and indemnification obligations.
The most recent analyst rating on (BTSG) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on BrightSpring Health Services, Inc. stock, see the BTSG Stock Forecast page.